This Article Full Text Full Text (PDF) All Versions of this Article: 35/11_suppl_1/2687    most recent 01.STR.0000143216.85349.9ev1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ratan, R. R. Articles by Chavez, J. Search for Related Content PubMed PubMed Citation Articles by Ratan, R. R. Articles by Chavez, J. Pubmed/NCBI databases Medline Plus Health Information Stroke Related Collections Acute coronary syndromes

(Stroke. 2004;35:2687.)
© 2004 American Heart Association, Inc.

Articles

Translation of Ischemic Preconditioning to the Patient

Prolyl Hydroxylase Inhibition and Hypoxia Inducible Factor-1 as Novel Targets for Stroke Therapy

Rajiv R. Ratan, MD PhD; Ambreena Siddiq, PhD; Leila Aminova, PhD; Philipp S. Lange, MD; Brett Langley, PhD; Issam Ayoub, MD; JoAnn Gensert, PhD Juan Chavez, PhD

From the Department of Neurology and Neuroscience, Burke/Cornell Medical Research Institute, Weill Medical College of Cornell, White Plains, NY.

Correspondence to Dr Rajiv R. Ratan, Burke/Cornell Medical Research Institute, 785 Mamaroneck Avenue, White Plains, NY 10605. E-mail rratan{at}caregroup.harvard.edu

Effective therapies for stroke must interdict multiple parallel and sequential pathophysiological events. A paradigm which offers insight into multivalent but thoughtfully coordinated protective programs is ischemic preconditioning. A central hypothesis of our group and others is that pharmacological agents that activate programs of gene expression normally induced by ischemic preconditioning will be effective agents for the prevention and treatment of stroke. Inhibitors of a class of enzymes, the hypoxia inducible factor-1 (HIF-1) prolyl hydroxylases stabilize the transcriptional activator HIF-1 and activate target genes involved in compensation for ischemia, including erythropoeitin (Epo) and vascular endothelial growth factor (VEGF). Here, we review evidence suggesting that the HIF-1 prolyl hyroxylases are inhibited during ischemic preconditioning and that pharmacological inhibitors of these enzymes are viable targets for stroke therapy.

Key Words: acute care • hypoxia • ischemia • stroke • transcription

This article has been cited by other articles:

				V. H. Haase Hypoxia-inducible factors in the kidney Am J Physiol Renal Physiol, August 1, 2006; 291(2): F271 - F281. [Abstract] [Full Text] [PDF]

				M. P. Biju, Y. Akai, N. Shrimanker, and V. H. Haase Protection of HIF-1-deficient primary renal tubular epithelial cells from hypoxia-induced cell death is glucose dependent Am J Physiol Renal Physiol, December 1, 2005; 289(6): F1217 - F1226. [Abstract] [Full Text] [PDF]